Evidence construction of Silibinin capsules against alcoholic liver disease based on a meta-analysis and systematic review
BackgroundIn recent years, the incidence of alcoholic liver disease (ALD) has rapidly increased worldwide, becoming a significant health issue. Silibinin capsules have shown potential in treating ALD, but clinical evidence is still insufficient. This meta-analysis aimed to evaluate the efficacy and...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1516204/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832542399969099776 |
|---|---|
| author | Yan Wang Yan Wang Wenmin Yang Wenmin Yang Yuan Yang Yuan Yang Xingning Liu Xingning Liu Lanfen Peng Lanfen Peng Qi Huang Qi Huang Qi Huang Kongli Fan Kongli Fan Rui Hu Rui Hu Jinyu Yi Jinyu Yi Xin Zhong Xin Zhong Jing Li Jialing Sun Xiaozhou Zhou Xiaozhou Zhou |
| author_facet | Yan Wang Yan Wang Wenmin Yang Wenmin Yang Yuan Yang Yuan Yang Xingning Liu Xingning Liu Lanfen Peng Lanfen Peng Qi Huang Qi Huang Qi Huang Kongli Fan Kongli Fan Rui Hu Rui Hu Jinyu Yi Jinyu Yi Xin Zhong Xin Zhong Jing Li Jialing Sun Xiaozhou Zhou Xiaozhou Zhou |
| author_sort | Yan Wang |
| collection | DOAJ |
| description | BackgroundIn recent years, the incidence of alcoholic liver disease (ALD) has rapidly increased worldwide, becoming a significant health issue. Silibinin capsules have shown potential in treating ALD, but clinical evidence is still insufficient. This meta-analysis aimed to evaluate the efficacy and safety of Silibinin capsules in the treatment of ALD.MethodsThe study was registered with PROSPERO (CRD42024509676). Randomized controlled trials (RCTs) were included from six databases, covering the period from database inception to 30 December 2023. Primary outcomes included liver function indicators such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), total bilirubin (TBIL), lipid indicators including triglycerides (TG) and total cholesterol (TC), coagulation indicators including prothrombin time (PT), liver fibrosis indicator (PC-III), and Effective Rate. Analysis was performed using Review Manager 5.4.1 and STATA 14.0.ResultsIn 15 RCTs involving 1,221 patients, compared to the non-Silibinin group, Silibinin capsules showed significant efficacy in terms of liver function, lipid levels, and effective rate in patients with ALD. Detailed parameters were as follows: ALT [SMD = −1.16, 95% CI (−1.84, −0.47)], AST [SMD = −1.56, 95% CI (−2.18, −0.95)], GGT [SMD = −1.48, 95% CI (−2.09, −0.87)], TBIL [SMD = −1.14, 95% CI (−2.16, −0.13)], TG [SMD = −1.29, 95% CI (−1.93, −0.66)], TC [SMD = −1.11, 95% CI (−1.61, −0.61)], PT [SMD = −0.01, 95% CI (−0.29, 0.26)], PC-III [SMD = −1.94, 95% CI (−3.04, −0.84)], and Effective Rate [OR = 3.60, 95% CI (2.28, 5.70)]. Importantly, Silibinin capsules exhibited a favorable safety profile, with only mild gastrointestinal reactions and reports of insomnia as adverse events.ConclusionThis review reveals the clinical efficacy and safety of Silibinin capsules in the treatment of ALD, and confirms that the drug is an effective adjuvant therapy to alleviate ALD. At present, the mechanism of action of this drug for ALD is still unclear, and we expect more experimental studies to prove the clinical value of Silibinin capsules.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=509676. |
| format | Article |
| id | doaj-art-bdbf8857f53f4a08a19c76326aa9843e |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-bdbf8857f53f4a08a19c76326aa9843e2025-02-04T05:28:04ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-02-011610.3389/fphar.2025.15162041516204Evidence construction of Silibinin capsules against alcoholic liver disease based on a meta-analysis and systematic reviewYan Wang0Yan Wang1Wenmin Yang2Wenmin Yang3Yuan Yang4Yuan Yang5Xingning Liu6Xingning Liu7Lanfen Peng8Lanfen Peng9Qi Huang10Qi Huang11Qi Huang12Kongli Fan13Kongli Fan14Rui Hu15Rui Hu16Jinyu Yi17Jinyu Yi18Xin Zhong19Xin Zhong20Jing Li21Jialing Sun22Xiaozhou Zhou23Xiaozhou Zhou24Department of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, ChinaDepartment of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, ChinaDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, ChinaDepartment of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, ChinaDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, ChinaDepartment of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, ChinaDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, ChinaDepartment of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, ChinaDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, ChinaDepartment of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, ChinaDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, ChinaDepartment of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, ChinaFaculty of Chinese Medicine, Macau University of Science and Technology, Taipa, Macao, ChinaDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, ChinaDepartment of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, ChinaDepartment of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, ChinaFaculty of Chinese Medicine, Macau University of Science and Technology, Taipa, Macao, ChinaDepartment of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, ChinaFaculty of Chinese Medicine, Macau University of Science and Technology, Taipa, Macao, ChinaDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, ChinaDepartment of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, ChinaDepartment of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, ChinaDepartment of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, ChinaDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, ChinaDepartment of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, ChinaBackgroundIn recent years, the incidence of alcoholic liver disease (ALD) has rapidly increased worldwide, becoming a significant health issue. Silibinin capsules have shown potential in treating ALD, but clinical evidence is still insufficient. This meta-analysis aimed to evaluate the efficacy and safety of Silibinin capsules in the treatment of ALD.MethodsThe study was registered with PROSPERO (CRD42024509676). Randomized controlled trials (RCTs) were included from six databases, covering the period from database inception to 30 December 2023. Primary outcomes included liver function indicators such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), total bilirubin (TBIL), lipid indicators including triglycerides (TG) and total cholesterol (TC), coagulation indicators including prothrombin time (PT), liver fibrosis indicator (PC-III), and Effective Rate. Analysis was performed using Review Manager 5.4.1 and STATA 14.0.ResultsIn 15 RCTs involving 1,221 patients, compared to the non-Silibinin group, Silibinin capsules showed significant efficacy in terms of liver function, lipid levels, and effective rate in patients with ALD. Detailed parameters were as follows: ALT [SMD = −1.16, 95% CI (−1.84, −0.47)], AST [SMD = −1.56, 95% CI (−2.18, −0.95)], GGT [SMD = −1.48, 95% CI (−2.09, −0.87)], TBIL [SMD = −1.14, 95% CI (−2.16, −0.13)], TG [SMD = −1.29, 95% CI (−1.93, −0.66)], TC [SMD = −1.11, 95% CI (−1.61, −0.61)], PT [SMD = −0.01, 95% CI (−0.29, 0.26)], PC-III [SMD = −1.94, 95% CI (−3.04, −0.84)], and Effective Rate [OR = 3.60, 95% CI (2.28, 5.70)]. Importantly, Silibinin capsules exhibited a favorable safety profile, with only mild gastrointestinal reactions and reports of insomnia as adverse events.ConclusionThis review reveals the clinical efficacy and safety of Silibinin capsules in the treatment of ALD, and confirms that the drug is an effective adjuvant therapy to alleviate ALD. At present, the mechanism of action of this drug for ALD is still unclear, and we expect more experimental studies to prove the clinical value of Silibinin capsules.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=509676.https://www.frontiersin.org/articles/10.3389/fphar.2025.1516204/fullSilibinin capsulesALDrctmeta-analysissystematic reviewChinese patent |
| spellingShingle | Yan Wang Yan Wang Wenmin Yang Wenmin Yang Yuan Yang Yuan Yang Xingning Liu Xingning Liu Lanfen Peng Lanfen Peng Qi Huang Qi Huang Qi Huang Kongli Fan Kongli Fan Rui Hu Rui Hu Jinyu Yi Jinyu Yi Xin Zhong Xin Zhong Jing Li Jialing Sun Xiaozhou Zhou Xiaozhou Zhou Evidence construction of Silibinin capsules against alcoholic liver disease based on a meta-analysis and systematic review Frontiers in Pharmacology Silibinin capsules ALD rct meta-analysis systematic review Chinese patent |
| title | Evidence construction of Silibinin capsules against alcoholic liver disease based on a meta-analysis and systematic review |
| title_full | Evidence construction of Silibinin capsules against alcoholic liver disease based on a meta-analysis and systematic review |
| title_fullStr | Evidence construction of Silibinin capsules against alcoholic liver disease based on a meta-analysis and systematic review |
| title_full_unstemmed | Evidence construction of Silibinin capsules against alcoholic liver disease based on a meta-analysis and systematic review |
| title_short | Evidence construction of Silibinin capsules against alcoholic liver disease based on a meta-analysis and systematic review |
| title_sort | evidence construction of silibinin capsules against alcoholic liver disease based on a meta analysis and systematic review |
| topic | Silibinin capsules ALD rct meta-analysis systematic review Chinese patent |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1516204/full |
| work_keys_str_mv | AT yanwang evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview AT yanwang evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview AT wenminyang evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview AT wenminyang evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview AT yuanyang evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview AT yuanyang evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview AT xingningliu evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview AT xingningliu evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview AT lanfenpeng evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview AT lanfenpeng evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview AT qihuang evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview AT qihuang evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview AT qihuang evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview AT konglifan evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview AT konglifan evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview AT ruihu evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview AT ruihu evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview AT jinyuyi evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview AT jinyuyi evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview AT xinzhong evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview AT xinzhong evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview AT jingli evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview AT jialingsun evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview AT xiaozhouzhou evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview AT xiaozhouzhou evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview |